{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06411288",
            "orgStudyIdInfo": {
                "id": "AOC 1001-CS3"
            },
            "organization": {
                "fullName": "Avidity Biosciences, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Global Study of Del-desiran for the Treatment of DM1",
            "officialTitle": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1",
            "acronym": "HARBOR",
            "therapeuticArea": [
                "Other"
            ],
            "study": "global-study-of-del-desiran-for-the-treatment-of"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-08",
            "studyFirstSubmitQcDate": "2024-05-08",
            "studyFirstPostDateStruct": {
                "date": "2024-05-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Avidity Biosciences, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1",
            "detailedDescription": "The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks.\n\nParticipants will be randomized to receive an intravenous infusion of either del-desiran or placebo at the clinical study site every 8 weeks for a total of 7 doses. The final dose will occur at Week 48, followed by a final assessment at Week 54.\n\nAfter completion of Week 54 assessments, eligible participants will have the option to enroll into an open label extension (OLE) study, pending regulatory approval.\n\nAn Independent Data Monitoring Committee (IDMC) comprised of members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals."
        },
        "conditionsModule": {
            "conditions": [
                "DM1",
                "Myotonic Dystrophy",
                "Myotonic Dystrophy 1",
                "Myotonia",
                "Myotonic Dystrophy Type 1 (DM1)",
                "Dystrophy Myotonic",
                "Myotonic Disorders",
                "Steinert Disease",
                "Steinert",
                "Myotonic Muscular Dystrophy"
            ],
            "keywords": [
                "DM1",
                "Myotonic Dystrophy",
                "Myotonic Dystrophy 1",
                "Myotonia",
                "Myotonic Dystrophy Type 1 (DM1)",
                "Dystrophy Myotonic",
                "Myotonic Disorders",
                "Steinert Disease",
                "Steinert",
                "Myotonic Muscular Dystrophy",
                "HARBOR",
                "Avidity Biosciences",
                "Avidity",
                "AOC 1001",
                "Del-desiran",
                "Delpacibart etedesiran"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Del-desiran",
                    "type": "EXPERIMENTAL",
                    "description": "Del-desiran (AOC 1001) will be administered seven times",
                    "interventionNames": [
                        "Drug: AOC 1001 (del-desiran)"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Saline will be administered seven times",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AOC 1001 (del-desiran)",
                    "description": "Del-desiran will be administered by intravenous (IV) infusion.",
                    "armGroupLabels": [
                        "Del-desiran"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo will be administered by intravenous (IV) infusion.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Hand function",
                    "description": "video Hand Opening Time (vHOT)",
                    "timeFrame": "Through Week 30"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Hand grip strength",
                    "description": "by dynamometer",
                    "timeFrame": "Through Week 30"
                },
                {
                    "measure": "Quantitative Muscle Testing composite score",
                    "description": "by dynamometer",
                    "timeFrame": "Through Week 30"
                },
                {
                    "measure": "Myotonic Dystrophy Type 1 activity and participation scale c",
                    "timeFrame": "Through Week 30"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Clinical and genetic diagnosis (CTG repeat \u2265 100) of DM1\n* Ability to walk independently (orthoses and ankle braces allowed) for at least 10 meters at screening\n\nKey Exclusion Criteria:\n\n* Breastfeeding, pregnancy, or intent to become pregnant during the study\n* Unwilling or unable to comply with contraceptive requirements\n* Abnormal lab values, conditions or diseases that would make the participant unsuitable for the study\n* Diabetes that is not adequately controlled\n* History of decompensated heart failure within 3 months of screening. Participants with preexisting pacemaker/ICD are not excluded.\n* Body Mass Index \\> 35 kg/m2 at Screening\n* Recently treated with an investigational drug or biological agent\n* Treatment with anti-myotonic medication within 5 half-lives or 14 days of baseline, whichever is longer, prior to baseline.\n\nNote: Additional protocol defined Inclusion and Exclusion criteria apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "16 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Avidity Biosciences, Inc.",
                    "role": "CONTACT",
                    "phone": "858-771-7038",
                    "email": "medinfo@aviditybio.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Rochester Medical Center",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "New York",
                    "zip": "14642",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth Luebbe",
                            "role": "CONTACT",
                            "email": "Elizabeth_Luebbe@URMC.Rochester.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.15478,
                        "lon": -77.61556
                    }
                },
                {
                    "facility": "Virginia Commonwealth University",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carino Jennings",
                            "role": "CONTACT",
                            "email": "Carino.Garza@vcuhealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009136",
                    "term": "Muscular Dystrophies"
                },
                {
                    "id": "D000009223",
                    "term": "Myotonic Dystrophy"
                },
                {
                    "id": "D000020967",
                    "term": "Myotonic Disorders"
                },
                {
                    "id": "D000009222",
                    "term": "Myotonia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020966",
                    "term": "Muscular Disorders, Atrophic"
                },
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000020879",
                    "term": "Neuromuscular Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12175",
                    "name": "Myotonic Dystrophy",
                    "asFound": "Myotonic Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12093",
                    "name": "Muscular Dystrophies",
                    "asFound": "Muscular Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12174",
                    "name": "Myotonia",
                    "asFound": "Myotonia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22698",
                    "name": "Myotonic Disorders",
                    "asFound": "Myotonic Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4589",
                    "name": "Atrophy",
                    "relevance": "LOW"
                },
                {
                    "id": "M22697",
                    "name": "Muscular Disorders, Atrophic",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22619",
                    "name": "Neuromuscular Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "T4024",
                    "name": "Myotonic Dystrophy",
                    "asFound": "Myotonic Dystrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4025",
                    "name": "Myotonic Dystrophy Type 1",
                    "asFound": "Myotonic Dystrophy Type 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3963",
                    "name": "Muscular Dystrophy",
                    "asFound": "Muscular Dystrophy",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}